Access key fund documentation and performance reports.
Our experienced team apply a rigorous stock-driven investment approach that focuses on improving fundamentals and incorporates an assessment of environmental, social & governance (ESG) factors. The scale and structure of the team allows them to efficiently cover a large and disparate universe while also drawing on the insight from other investment teams across the business. Our style-agnostic portfolios are driven by our highest conviction investment ideas implemented with rigorous risk control.
We offer strategies that tap into both the attractive income and growth potential of the broader emerging market equity asset class and the exciting capital growth prospects inherent in smaller companies.
For further information on the risks and risk profiles of our funds, please refer to the relevant KIID and Prospectus.
The value of an investment and any income from it can go down as well as up and can fluctuate in response to changes in currency exchange rates. Investors may not get back the original amount invested.
Emerging market equities strategies
Global emerging market equities team
Head of Global Emerging Market Equities
Read more about the funds
Explore our equities range
Our range of global equity funds is underpinned by a robust, repeatable investment process to meet clients' objectives across capital growth, income and responsible investing.
Covering both continental and pan-European regions, our range of equity funds focus on identifying companies with improving fundamentals.
Re-enter the dragon: What China’s recovery from COVID-19 means for emerging markets
7 Apr 2020
We explore the impact of COVID-19 on China and emerging market debt and equities.
Are investors too complacent about the coronavirus?
21 Feb 2020
In the latest of our editorial series, Link, AIQ brings members of Aviva Investors’ investment strategy, equity and debt teams together to discuss the prospects for financial markets and the world economy in the face of the coronavirus epidemic.
Cwtch: Has capitalism gone cuddly?
18 Feb 2020
In the first of a new editorial series, Link, AIQ brings together people from across Aviva Investors to debate topical themes. Mirza Baig and Stephanie Niven consider whether CEO claims about running businesses for multiple stakeholders rather than shareholders alone is a grand idea or just plain grandstanding.
Multi-asset allocation views: Why the bull run in global equities could continue
12 Feb 2020
Sunil Krishnan discusses the conditions for a continued rise in global equities, the potential of Japanese and US equities to outperform from a regional perspective, and some attractive features of emerging markets – particularly Brazil – which may have been overlooked.
In a complex market, investors need to connect information signals more effectively
19 Nov 2019
A growing body of research suggests equity investors are poor at recognising the connections and interrelationships between companies. A fresh approach is needed, argues Mikhail Zverev, head of global equities at Aviva Investors.
5G: Anatomy of an equity investment idea
11 Nov 2019
The evolution of wireless technology has fuelled a host of new mobile applications and helped propel companies such as Netflix. 5G, its next iteration, promises speeds up to 20 times faster than the current 4G. But to think only in terms of speed severely underestimates 5G’s potential to fundamentally transform the business landscape – though not without tremendous risk.
Back to the future: Dr Eric Topol on AI in healthcare
3 Oct 2019
In the final article in our series on healthcare, we speak to the renowned cardiologist and author Eric Topol about his new book, Deep Medicine.
Substance over style?
30 Sep 2019
Why an agnostic approach beats equity style biases.
Big Tech bets on healthcare
25 Sep 2019
In the third of a four-part series on healthcare, we focus on technology. New tech innovations promise to deliver better treatments and cost efficiencies – but concerns over data protection and flawed AI persist.
Biotech disrupters shake up the drug discovery business
18 Sep 2019
In the second of a four-part series on healthcare, we look at how competition between Big Pharma, Chinese biotech and Silicon Valley is transforming the landscape of drug discovery.
Investors must hold bad bosses to account
16 Sep 2019
Institutional shareholders need to be as agile and active as private equity in dealing with failures of leadership.
Medicine, politics and investing: Tensions abound
12 Sep 2019
In the first of a four-part series on global healthcare, we look at why the sector is likely to take centre stage in the 2020 US elections and what this means for investors.
As China soars, emerging market investors need a rethink
21 Aug 2019
With China set to dominate EM equity indices over the coming decades, investors need to adjust their approach to the asset class, argues Alistair Way.
BP vote demonstrates power of engagement
28 Jun 2019
As climate change rises up the political agenda throughout the West and beyond, shareholders have an important role to play in limiting global fossil fuel consumption by pressuring oil companies to amend their strategies, argues Sora Utzinger.
'Fairtrade for finance' should be a badge of honour - not a rubber stamp
21 Jun 2019
A Fairtrade-style kitemark for responsible investment is in the pipeline. Properly implemented, the initiative should improve industry standards on ESG, writes Steve Waygood.
Talking with David Cumming
6 Jun 2019
Talking equities, markets and playing the piano with David Cumming, Chief Investment Officer, Aviva Investors and Richard Romer-Lee, Square Mile.